Literature DB >> 17100545

Stability of IGF-I concentration despite divergent results of repeated GH stimulating tests indicates poor reproducibility of test results.

Maciej Hilczer1, Joahna Smyczynska, Renata Stawerska, Andrej Lewinski.   

Abstract

OBJECTIVE: Growth hormone (GH) secretion is routinely assessed in provocative tests. However, some limitations of these tests have been reported, including a weak correlation between spontaneous GH secretion and GH peak in stimulating tests, poor reproducibility of test results and normalisation of previously decreased GH response to stimulation in the repeated provocative tests. The observed discrepancies between the results of consecutive GH stimulating tests in the same patient may be explained either by real changes in GH secretion or by the poor reproducibility of GH response to stimulation. Normalisation of previously decreased GH secretion should entail the increase of insulin-like growth factor-I (IGF-I) concentration, while stability of IGF-I secretion despite divergent GH response to stimulation in repeated tests might indicate the poor reproducibility of GH stimulating tests. continue with The aim of the study was a comparison of GH peak in repeated stimulating tests and of corresponding, simultaneously measured IGF-I concentration.
METHODS: The investigation comprised 84 children with short stature who underwent repeated GH tests and IGF-I evaluation. In 60 patients each of two different tests (with clonidine and with glucagon, in standard doses) was performed twice, together with IGF-I measurement during both evaluations. In 20 patients (remaining in the same pubertal stage during the time period between the procedures in question) at least one test, together with IGF-I measurement, was repeated within one year.
RESULTS: The correlation between the results of GH tests, repeated during the two evaluations, was weak (r=0.22, p<0.05 for all patients and r=0.25, p<0.05 for the patients examined 2 times within 1 year), with the high within-subject variability (43.4 % and 59.5 %, respectively). Conversely, the correlation between two values of IGF-I SDS was good both for all patients (r=0.65, p<0.05) and especially for the patients examined twice within 1 year (r=0.96, p<0.05), with low within-subject variability for the latter subgroup of patients (11.2 %). The same GH stimulating tests, performed twice in the same patient, led to different conclusions (either the confirmation of GHD diagnosis or its exclusion) in most of examined patients. Poor reproducibility of GH stimulating tests, rather than the possibility of short-term changes in GH secretion, was confirmed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17100545

Source DB:  PubMed          Journal:  Endocr Regul        ISSN: 1210-0668


  9 in total

1.  Correlation between serum IGF-1 and blood lead level in short stature children and adolescent with growth hormone deficiency.

Authors:  Yan Xu; Ming-Chao Liu; Pei Wang; Bei Xu; Xin-Qin Liu; Zhi-Ping Zhang; Li-Fen Ren; Qing Qin; Yue-Yun Ma; Wen-Jing Luo; Xiao-Ke Hao
Journal:  Int J Clin Exp Med       Date:  2014-04-15

2.  Transcriptomics and machine learning predict diagnosis and severity of growth hormone deficiency.

Authors:  Philip G Murray; Adam Stevens; Chiara De Leonibus; Ekaterina Koledova; Pierre Chatelain; Peter E Clayton
Journal:  JCI Insight       Date:  2018-04-05

3.  Specific miRNAs Change After 3 Months of GH treatment and Contribute to Explain the Growth Response After 12 Months.

Authors:  Cecilia Catellani; Gloria Ravegnini; Chiara Sartori; Beatrice Righi; Pietro Lazzeroni; Laura Bonvicini; Silvia Poluzzi; Francesca Cirillo; Barbara Predieri; Lorenzo Iughetti; Paolo Giorgi Rossi; Sabrina Angelini; Maria Elisabeth Street
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-22       Impact factor: 6.055

4.  Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: a randomized, placebo-controlled, multicenter trial for one to three years.

Authors:  Nelly Mauras; Lilliam Gonzalez de Pijem; Helen Y Hsiang; Paul Desrosiers; Robert Rapaport; I David Schwartz; Karen Oerter Klein; Ravinder J Singh; Anna Miyamoto; Kim Bishop
Journal:  J Clin Endocrinol Metab       Date:  2007-12-28       Impact factor: 5.958

5.  Do IGF-I concentrations better reflect growth hormone (GH) action in children with short stature than the results of GH stimulating tests? Evidence from the simultaneous assessment of thyroid function.

Authors:  Joanna Smyczyńska; Renata Stawerska; Andrzej Lewiński; Maciej Hilczer
Journal:  Thyroid Res       Date:  2011-01-13

6.  Towards identification of molecular mechanisms of short stature.

Authors:  Lindsey A Waldman; Dennis J Chia
Journal:  Int J Pediatr Endocrinol       Date:  2013-11-20

7.  Effects of Helicobacter pylori Infection on Ghrelin and Insulin-like Growth Factor 1 Secretion in Children with Idiopathic Short Stature.

Authors:  Marzena Kolasa-Kicińska; Renata Stawerska; Paweł Stawerski; Andrzej Kałużyński; Elżbieta Czkwianianc; Andrzej Lewiński
Journal:  J Clin Med       Date:  2022-10-04       Impact factor: 4.964

8.  Influence of biochemical diagnosis of growth hormone deficiency on replacement therapy response and retesting results at adult height.

Authors:  Giulia Rodari; E Profka; F Giacchetti; I Cavenaghi; M Arosio; C Giavoli
Journal:  Sci Rep       Date:  2021-07-15       Impact factor: 4.379

9.  Pre-treatment growth and IGF-I deficiency as main predictors of response to growth hormone therapy in neural models.

Authors:  Urszula Smyczyńska; Joanna Smyczyńska; Maciej Hilczer; Renata Stawerska; Ryszard Tadeusiewicz; Andrzej Lewiński
Journal:  Endocr Connect       Date:  2017-12-14       Impact factor: 3.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.